Written Question · S5W-24624 · Session 5
For what reason it has not provided an answer to question S5W-24139, which was due on 31 July 2019, and whether it will provide an update o…
The question
To ask the Scottish Government for what reason it has not provided an answer to question S5W-24139, which was due on 31 July 2019, and whether it will provide an update on any progress that has been made in bringing the United States-based mesh surgeon, Dr Veronikis, to Scotland.
The answer
The Scottish Government provided an answer to S5W-24139 prior to the due date of 31 July. However, due to a technical fault within Parliament
- of which the Scottish Government was not aware
- this was not subsequently issued to the member.
As indicated in a letter to the member dated 15 August, I welcome Dr Veronikis’ offer to come to Scotland, and am very grateful for it. However, as I indicated in my 26 June statement to Parliament, Dr Veronikis can only practice medicine here in Scotland, and work with our clinicians, once he obtains registration with the GMC.
In order to register temporarily with the GMC, there are a number of requirements that a visiting specialist is required to fulfil. This includes providing evidence of qualifications, a letter of introduction from a Royal College and, from the country they are presently practicing in, evidence of their licence to practice and a certificate of good standing. Officials have encouraged Dr Veronikis to begin gathering the required evidence.
Furthermore, the GMC also require evidence of employment in the UK and, in order to fulfil this requirement, Dr Veronikis must obtain a contract from a Health Board, in this case NHS Greater Glasgow and Clyde. This will, of course, be offered on the basis that the merit of any visit is clearly proven. In this context, it is important that professional diligence is discharged and is demonstrated to everyone’s satisfaction. I confirm that this process is underway, with the Chair and other key members of the Short Life Working Group on mesh complications presently liaising with Dr Veronikis.
An important step in this process is an initial, fact-finding and educational visit by Scottish clinicians to Dr Veronikis in the US. During this visit further arrangements for clinical cooperation, learning and sharing experience – in Scotland – will be considered. Officials are presently making arrangements for this visit which, taking into account the present commitments – clinical and otherwise – of both Scotland’s clinicians and Dr Veronikis, is being planned for early autumn.
Applying due diligence in this way will help to ensure that Dr Veronikis has the necessary professional sponsorship and that NHS Greater Glasgow and Clyde will be able to offer him a contract.
I want to ensure that patients in Scotland have access to the best possible care for mesh complications. This will inevitably involve a degree of comparison and benchmarking, and I view any visit by Dr Veronikis an important step toward this. However, any such visit can only take place in the context of agreement and regulatory approval by the GMC. Officials are taking the steps outlined above in order to maximise the likelihood of this being achieved.
- of which the Scottish Government was not aware
- this was not subsequently issued to the member.
As indicated in a letter to the member dated 15 August, I welcome Dr Veronikis’ offer to come to Scotland, and am very grateful for it. However, as I indicated in my 26 June statement to Parliament, Dr Veronikis can only practice medicine here in Scotland, and work with our clinicians, once he obtains registration with the GMC.
In order to register temporarily with the GMC, there are a number of requirements that a visiting specialist is required to fulfil. This includes providing evidence of qualifications, a letter of introduction from a Royal College and, from the country they are presently practicing in, evidence of their licence to practice and a certificate of good standing. Officials have encouraged Dr Veronikis to begin gathering the required evidence.
Furthermore, the GMC also require evidence of employment in the UK and, in order to fulfil this requirement, Dr Veronikis must obtain a contract from a Health Board, in this case NHS Greater Glasgow and Clyde. This will, of course, be offered on the basis that the merit of any visit is clearly proven. In this context, it is important that professional diligence is discharged and is demonstrated to everyone’s satisfaction. I confirm that this process is underway, with the Chair and other key members of the Short Life Working Group on mesh complications presently liaising with Dr Veronikis.
An important step in this process is an initial, fact-finding and educational visit by Scottish clinicians to Dr Veronikis in the US. During this visit further arrangements for clinical cooperation, learning and sharing experience – in Scotland – will be considered. Officials are presently making arrangements for this visit which, taking into account the present commitments – clinical and otherwise – of both Scotland’s clinicians and Dr Veronikis, is being planned for early autumn.
Applying due diligence in this way will help to ensure that Dr Veronikis has the necessary professional sponsorship and that NHS Greater Glasgow and Clyde will be able to offer him a contract.
I want to ensure that patients in Scotland have access to the best possible care for mesh complications. This will inevitably involve a degree of comparison and benchmarking, and I view any visit by Dr Veronikis an important step toward this. However, any such visit can only take place in the context of agreement and regulatory approval by the GMC. Officials are taking the steps outlined above in order to maximise the likelihood of this being achieved.
In the Official Report
No contribution in the Official Report cites S5W-24624 by reference.